Targeted Drug Delivery for Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) still represents an incurable disorder that may progress to other more aggressive types of cancer despite the available therapy and the development that has been reached in the immunophenotypic and mutational status characterization of CLL. Hence, innovative therapeutics strategies are required together with the advancement in chemo-immunotherapy and targeted treatments. Parallelly, more focus should be put on the drug delivery process to improve the effectiveness/toxicity ratio of both conventional and new drugs and reduce the risk of drug resistance. In the present review, different types of nanocarriers that can be harnessed against CLL, their features, their capabilities in targeting CLL cells, and the latest relevant data are discussed. We provide an integral description of each nanocarrier, including lipidic, polymeric, and inorganic carriers, aiming to offer a constructive resource for the rational design of potential nanomedicines to advance the fight against CLL.

Automated summary

Chronic lymphocytic leukemia (CLL) is an incurable disorder that requires innovative therapeutic strategies and improved drug delivery process for better treatment effectiveness. This review discusses the use of different types of nanocarriers in fighting against CLL and their features.